Based on the literature reports combined with the results of the network pharmacology in this study, the authors found that the PI3K‐Akt and TP53 signaling‐related pathways were important core pathways for luteolin to play a role in the treatment of IC/BPS [16, 17, 18, 24, 25, 26]. This evidence concerns the gene TP53 and Bartsocas-Papas syndrome 1.